Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Medical Manufacturing, Economic Development, and Sustainability (MMEDS) Act of 2025 seeks to strengthen domestic medical device and equipment manufacturing while improving pandemic preparedness for vulnerable populations. The bill provides substantial tax incentives—including 40% credits on wages and equipment costs—to companies that operate medical manufacturing facilities in economically distressed areas, with even higher credits (50–60%) for facilities that relocate production from foreign countries or manufacture products addressing critical health threats. It also establishes tax credits for domestic manufacturers that purchase supplies and services from economically distressed zones. Additionally, the legislation expands the definition of medical countermeasures to include treatments for underlying diseases like heart disease and diabetes when combined with pandemic threats, creates a new "population health products" category, and requires federal agencies to coordinate rapid distribution of approved health products during epidemics while examining whether vulnerable groups—including the elderly, minorities, veterans, and those with chronic conditions—suffered disproportionate harm during past pandemics. The bill takes effect January 1, 2025, with implementing regulations required within 60 days of enactment and a 90-day report mandated on pandemic disparities and future treatment incentives.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.